The median age of the patients was 83 years and 108 were men, and 57 were women. This patient population was not eligible for anthracycline-based chemoimmunotherapy (eg, doxorubicin or epirubicin) due to age or clinically significant comorbidities. Patients received epcoritamab by injection using a step-up dosing schedule, beginning with low doses (0.16 mg on day 1 and 0.8 mg on day 8 of cycle 1) before increasing to the full 48-mg dose.